Actionable news
All posts from Actionable news
Actionable news in LTBR: Lightbridge Corporation,

Kiadis Pharma Utilizes BioLife Solutions HypoThermosol® to Improve Viability and Shelf Life of Donor Leukocytes in Clinical Trial of ATIR101™ T Cell Therapy for Blood Cancers

BOTHELL, Wash., Oct. 19, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Amsterdam-based Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T cell immunotherapy treatments for blood cancers and inherited blood disorders, has incorporated the Company's clinical grade HypoThermosol cell and tissue storage and shipping medium into its collection process for donor leukocytes that forms the basis of Kiadis' ATIR101 T cell product targeting patients with various blood cancers.

In addition to Kiadis, a large majority of the currently active private and public cellular immunotherapy companies have adopted BioLife's biopreservation media products including HypoThermosol and CryoStor to extend stability and improve viability and functional recovery of starting material and manufactured cell products.

Mike Rice, BioLife's President & CEO, said, "We are very pleased to support Kiadis in their development of potentially life saving cellular immunotherapies for cancer patients. It's very satisfying to see the clinical community focus on shelf life and viability as key criteria for potential commercialization of novel cell therapies. HypoThermosol and our companion CryoStor freeze media are now embedded in over 200 pre-clinical validations...